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Background: Diet is an important component of type 2 diabetes therapy. Low adherence to current therapeutic
diets points out to the need for alternative dietary approaches. This study evaluated the effect of a different dietary
approach, the macrobiotic Ma-Pi 2 diet, and compared it with standard diets recommended for patients with type
2 diabetes.
Methods: A randomized, controlled, open-label, 21-day trial was undertaken in patients with type 2 diabetes
comparing the Ma-Pi 2 diet with standard (control) diet recommended by professional societies for treatment
of type 2 diabetes. Changes in fasting blood glucose (FBG) and post-prandial blood glucose (PPBG) were primary
outcomes. HbA1c, insulin resistance (IR), lipid panel and anthropometrics were secondary outcomes.
Results: After correcting for age, gender, BMI at baseline, and physical activity, there was a significantly greater
reduction in the primary outcomes FBG (95% CI: 1.79; 13.46) and PPBG (95% CI: 5.39; 31.44) in those patients receiving
the Ma-Pi 2 diet compared with those receiving the control diet. Statistically significantly greater reductions in the
secondary outcomes, HbA1c (95% CI: 1.28; 5.46), insulin resistance, total cholesterol, LDL cholesterol and LDL/HDL ratio,
BMI, body weight, waist and hip circumference were also found in the Ma-Pi 2 diet group compared with the control
diet group. The latter group had a significantly greater reduction of triglycerides compared with the Ma-Pi 2 diet
group.
Conclusions: Intervention with a short-term Ma-Pi 2 diet resulted in significantly greater improvements in metabolic
control in patients with type 2 diabetes compared with intervention with standard diets recommended for these
patients.
Trial registration: Current Controlled Trials ISRCTN10467793.
Keywords: Fasting blood glucose, Macrobiotic diet, Type 2 diabetesBackground
Type 2 diabetes is currently one of the most challenging
problems facing national healthcare systems worldwide
[1]. Nutritional therapy (as part of life-style interven-
tion), with or without additional drug treatment, repre-
sents an effective option for managing this disease [2].
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unless otherwise stated.can be difficult, since cultural preferences and economic
conditions influence patient acceptance of, and adher-
ence to, recommended diets [3].
In general, consumption of healthy, plant-based diets
which are low in saturated fat and refined carbohydrates
but high in whole grains, vegetables, legumes and fruits,
coupled with appropriate exercise regimens, is recom-
mended for patients with type 2 diabetes [4-7]. Add-
itionally, reduction in the intake of carbohydrates with a
high glycemic index has been shown to result in signifi-
cant improvements in glucose tolerance and body weighttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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similar energy content [8]. The International Diabetes
Federation (IDF) and the American Diabetes Association
(ADA) have issued diet recommendations for patients
with type 2 diabetes [9,10], however, alternative approaches
need to be investigated because of the frequent low adher-
ence of the currently recommended diets in the manage-
ment of type 2 diabetes [11].
Macrobiotic diets, originally derived from an ancient
Eastern philosophy of life, and updated for Western cul-
ture by the Japanese philosopher Georges Ohsawa [12],
contain a large proportion of whole grains. The Ma-Pi 2
diet, conceived by Mario Pianesi, is a kind of macrobi-
otic diet; it is high in dietary fiber, which is in line with
dietary recommendations by the Academy of Nutrition
and Dietetics [13]. High-fiber diet may induced several
health benefits such as prevention or reduction of bowel
disorders and decreased risk of the development of cor-
onary heart disease and type 2 diabetes [14,15]. The
Ma-Pi 2 diet is also rich in complex carbohydrates, whole
grains, vegetables and legumes, fermented products, sea
salt and green tea, without fat or protein from animal
sources (including milk and dairy products) and no added
sugars. These features are designed to achieve optimal glu-
cose control, lower insulin requirement, prolong the time
of glucose absorption, increase insulin sensitivity, reduce
total cholesterol and triglyceride levels in plasma, improve
body weight control and lower systemic blood pressure
[16-19]. Additionally, the Ma-Pi 2 diet appears to have
antioxidant properties and prebiotic or probiotic effects
[20]. This may alter the composition of gut microbiota,
which in turn may affect the glycemic control [21,22].
In previous uncontrolled intervention studies of 3-
weeks’ duration, patients with type 2 diabetes following
the Ma-Pi 2 diet have exhibited reduced HbA1c, choles-
terol, triglycerides, and blood pressure [23,24]. We re-
port here on the first randomized comparative trial
which compares the Ma-Pi 2 diet with the dietary guide-
lines for type 2 diabetes recommended by professional
societies in Italy [25].
Methods
Trial design
The study was a 21-day, controlled open-label trial in
which participants were randomized (1:1 ratio) to the
Ma-Pi 2 macrobiotic diet or to a diet based on dietary
recommendations guidelines for type 2 diabetes [25].
The trial took place in the spring of 2013 at 2 closed site
hotels in Italy. Throughout the trial, participants stayed
at two different hotels according to the type of diet they
were randomized to. The hotels were localized in the
same geographic area, very close to each other, approxi-
mately a 20 minutes’ drive distance between them. Pa-
tients were recruited from the Endocrinology andDiabetes Department at University Campus Bio-Medico.
The trial was conducted in accordance with the Declar-
ation of Helsinki and the Good Clinical Practice guide-
lines and approved by the Institutional Review Board of
University Campus Bio-Medico.
Inclusion and exclusion criteria
Overweight or obese (BMI 27–45 kg/m2) males and fe-
males, aged 40–75 years affected by type 2 diabetes were
recruited by the medical team during regular visits to the
Department of Endocrinology and Diabetes of the Univer-
sity Campus Bio-Medico in Rome, Italy. Additional inclu-
sion criteria were a diagnosis of type 2 diabetes at least
1 year prior to the start of the trial and management with
dietary intervention, oral hypoglycemic drugs (OADs), or
both for 6 months prior to study entry. Identification of
the presence of associated metabolic syndrome was made
in accordance to the National Cholesterol Education
Program Adult Treatment Panel III criteria, even though
it was not an inclusion criteria [26]. Exclusion criteria in-
cluded current use of insulin, or use at any time in the
2 years prior to the study, current use of corticosteroid
therapy or any other drug that could interfere with carbo-
hydrate metabolism, alcohol abuse, pregnancy, or already
following a macrobiotic diet.
Interventions
Participants’ eating habits prior to study entry were
assessed using qualitative and quantitative questionnaires,
and the energy and nutritional content of their diet was
evaluated based on the answers given. Group assignment
to treatment was blinded for personnel involved in collec-
tion of follow-up data and for personnel analyzing blood
samples until data was locked for statistical analysis.
Participants were randomized to either the Ma-Pi 2
diet or a control diet according to the dietary guidelines
for type 2 diabetes. The Ma-Pi 2 diet consisted of whole
grains, vegetables and legumes. Beicha tea (roasted green
tea) represented the main source of liquids, while the
control diet was adapted to the Mediterranean culinary
style. For both groups, energy intake was restricted by
limiting calories to 1900 kcal/day and 1700 kcal/day for
males and females, respectively. The diets were isocaloric
but differed in nutrient composition. Ma-Pi 2 diet derived
72% of energy from carbohydrate, 18% from fat, and 10%
energy from protein, fiber equal to 30 g/1000 kcal, while
the control diet 50% from carbohydrate, 20% from pro-
tein, and 30% from fat, fiber ≥20 g/1000 kcal. Alcohol con-
sumption was forbidden. Both diets provided 5 meals per
day, with energy intake being divided between meals, 20%
calories at breakfast, 30% calories at lunch and 30% calories
at dinner. Two snacks were administered at approximately
2.5 hours after breakfast and lunch, respectively, each con-
tributing 10% of the calories per day (Additional file 1).
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then repeated at the end of the period for another 11 days.
Each daily menu was carefully planned and completed
with recipes for each dish. Nutritional analysis and menu
planning was developed with MètaDieta® Software using
the Italian Food Composition Tables edited by the
National Institute for Food and Nutrition Research (INRAN)
[27]. Each menu cycle was ready a week before the beginning
of the study to ensure that each recipe was tested by the
cooks in order to reproduce it consistently. At this stage
and throughout the intervention study, dietitians checked
and weighed each portion size before and after cooking to
make sure that subjects in both groups consumed equiva-
lent amounts of energy and that macronutrient content
was respected. Each subject was informed that a plate
waste greater than or equal to 5% of the total daily food
amount meant dismissal from the trial. Throughout the
trial, participants stayed at two different hotels according
to the type of the diet they were randomized. Meal con-
sumption was strictly controlled in order to evaluate diet-
ary compliance during the trial. Participants had their
meals together with physicians and dietitians who could
check their adherence to study protocol. Dietary adher-
ence was defined as absence of any transgression from the
assigned diet. Those subjects who attended meal session
for fewer than 20 out of 21 days were considered non-
adherent.
Participants were asked not to alter their exercise habits
during the intervention period. Physical activity was
assessed daily using a pedometer (Tri-axial activity monitor
XL-18/XL-18 CN-AND A&D Medical-California-USA). In
addition they were instructed to continue their pre-
study OAD doses without modification throughout
the study, unless hypoglycemic symptoms were accom-
panied by a capillary glucose reading <70 mg/dL. In such
cases hypoglycemic medications were reduced for partici-
pant safety.
Outcome measures
The primary outcomes of this study were the percentage
change in Fasting Blood Glucose (FBG) and Post Prandial
Blood Glucose (PPBG) levels from baseline (T0) to the 21st
day of treatment (T21) in Ma-Pi 2 group compared to the
control group. Secondary outcomes included percentage
change from baseline in plasma concentrations of HbA1c,
total cholesterol, LDL cholesterol (LDLc), HDL cholesterol
(HDLc), LDL/HDL ratio, and percentage change from
baseline of insulin resistance, body weight, BMI, waist and
hip circumference, and number of patients who achieved
target values of FBG ≤110 mg/dl and PPBG ≤140 mg/dl.
FBG and PPBG were measured daily from T0 to T21
by the medical staff using capillary blood glucose meters
(Bluecare, Biochemical Systems International, Arezzo,
Italy). The fasting blood glucose was measured rightbefore meals and the post-prandial blood glucose was
measured 2-h after lunch. For all participants, venous
blood samples were obtained early in the morning after a
12 hour fasting period. All biochemical and anthropome-
trical measures were assessed at T0 and T21 by the central
laboratory (University Campus Bio-Medico, Rome). Insu-
lin resistance was calculated using the homeostasis model
assessment of insulin resistance (HOMA-IR) [28].
Body weight was measured at T0 and T21 before break-
fast using a digital scale accurate to 0.1 kg, waist circum-
ference was measured with a tape measure placed 2.5 cm
above the umbilicus. Hip circumference was measured at
the maximal protrusion of the buttocks.
All patient and investigator-reported adverse events
(AEs) were recorded at each visit.
Statistical analyses
This study required 28 randomized patients per group
with 80% power to detect a difference of at least 12 per-
centage points reduction in mean FBG and PPBG from
baseline between Ma-Pi 2 and control groups (with a 2-
sided type I error at 0.05), assuming a standard deviation
of ≤15% and a maximum dropout rate of 11%.
To detect a 0.25 percentage point between-group differ-
ence in HbA1c from baseline (the main secondary end-
point) with 80% power, a p value at the 5% level with an
assumed SD of 0.3% and 10% estimated withdrawal, 27
participants were required per group.
The primary analysis was based on a modified
intention-to-treat principle and it was carried out for all
patients who had FBG and PPBG results for at least the
first week following randomization. A non-parametric
approach was chosen for the statistical analysis since
outcome variables were found to be of non-normal dis-
tribution (using the Shapiro test). Quantitative variables
were summarized using percentiles (median and inter-
quartile range). Comparisons between treatment groups
were performed using the Wilcoxon rank-sum test and
95% confidence intervals (95% CI) for median values. Ab-
solute and percentage frequencies were used for qualita-
tive variables and the Fisher exact test was applied for
group comparisons.
The 2 groups were compared at T0 to test whether pa-
tients were similar in terms of demographic and an-
thropometrics characteristics, and lipid and carbohydrate
metabolic parameters. The percent variations between
values measured at T0 and T21 were calculated as efficacy
variables for the primary (FBG and PPBG), and secondary
end-points (HbA1c, HOMA-IR, total cholesterol, LDLc,
HDLc, LDL/HDL ratio, triglycerides, BMI, waist and hip
circumference).
A bivariate analysis was performed to compare mea-
sures changes between the Ma-Pi 2 diet group and the
control group and results were graphically represented
Primary outcomes 
Secondary outcomes 
Figure 1 (See legend on next page.)
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Figure 1 Reduction in primary and secondary outcomes from baseline to T21 in the Ma-Pi 2 group vs. controls. Primary outcomes -
Percentage change in FBG and PPBG from baseline to T21 in the Ma-Pi 2 group vs. control group. The figure represents the results of the bivariate
analysis when the Ma-Pi 2 and control groups were compared in the percentage change between T0 and T21 of the efficacy variables (non-adjusted
values). Secondary outcomes - Percentage change in HbA1c, lipid panel, BMI, weight, hip circumference and waist circumference from baseline to T21
in the Ma-Pi 2 group vs. control group. The figure represents the results of the bivariate analysis when the Ma-Pi 2 and control groups were compared
in the percentage change between T0 and T21 of the efficacy variables (non-adjusted values).
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sion analysis [29] was performed to estimate the effect of
the diet (Ma-Pi 2 vs. control, explanatory variable) on the
median percentage change occurred in each measured
variable as (dependent variables), between T0 and T21.
Each model was adjusted for those variables that could
potentially affected the percent changes in the dependent
variables, i.e. gender, age, BMI at baseline, and physical ac-
tivity done by subjects during 21 days of the treatment
(measured as the median number of kilometers walked
per day). When HOMA-IR was analyzed, the wrist cir-
cumference was included in the model as covariate for ad-
justment. Wrist circumference is recognized a valid and
easy marker to measure insulin resistance [30,31]. The re-
sults of linear quantile regression analysis were expressed
as point and interval estimates of regression coefficients;
when the coefficient was positive, the measured variable
reduction was related to Ma-Pi 2 diet effect and when the
coefficient was negative the reduction was related to the
control diet. When the 95% CI’s did not include zero, re-
gression coefficients were considered statistically signifi-
cant (Table 1).
Patients with values of FBG ≤110 mg/dl and of
PPBG ≤140 mg/dl were considered to have reached
target values. Group comparisons in terms of percent-
age of patients achieving and maintaining those target
levels after 21 days were performed using McNemar’s test
to estimate the differences between proportions in the 2
groups and their relative 95% CI’s; when the 95% CI’s did
not include zero, the differences were statistically signifi-
cant (Table 2).
A ranked-based nonparametric analysis for longitudinal
data was used to compare the time trend in absolute values
of FBG and PPBG over 21 days of dietary intervention in
Ma-Pi 2 and control groups. The effect of diet, time and
their interaction were evaluated; results were graphically
represented by plotting the median values of the daily mea-
surements of FBG and PPBG in the two groups (Figure 2).
All statistical analyses were performed using R statis-
tical package (Foundation for Statistical Computing,
Vienna, Austria) and statistical significance was assessed
at a level of probability of 0.05.
Results
A total of 200 patients were screened and 56 were con-
sidered eligible for recruitment.Baseline demographic and clinical features of patients
are presented in Table 3. There were no significant differ-
ences between groups. Analysis of diets in the 6 months
prior to the trial showed little difference between groups,
with an average daily energy intake of 1988 (SD 368.2)
kcal for the Ma-Pi 2 group and 1964 (SD 294.3) kcal for
the control group (p = 0.802). Nutritional composition
was also similar in the Ma-Pi 2 group (18.2% protein,
36.2% fat, 45.6% carbohydrate, 10.3 g/1000 kcal of fiber)
versus the control group (19.3% protein, 35.4% fat, 45.3%
carbohydrate, 10.8 g/1000 kcal of fiber).
The 56 eligible patients were randomly assigned to the
Ma-Pi 2 diet group (n = 28) and the control group (n = 28).
Reasons for exclusion were failure to meet inclusion criteria
(n = 90), inability to attend residential schedule (n = 45),
and failure to keep interview appointment (n = 9). The
CONSORT diagram reflecting flow of study participants
through the study is shown in Figure 3. Both groups experi-
enced drop outs after randomization but before receiving
any intervention; 3 patients in the Ma-Pi 2 diet group and 2
in the control group. Reasons for discontinuation included
patient reluctance to change diet (1 patient in the Ma-Pi 2
group) and personal problems that prevented patients
remaining in the assigned hotel for the study duration (2
patients in the Ma-Pi 2 group and 2 patients in the control
group). Therefore a total of 51 patients, 25 in the Ma-Pi 2
group and 26 in the control group, completed the trial
and were included in the modified ITT (mITT) analysis.
The modified intention-to-treat was carried out for all pa-
tients who had FBG and PPBG results for at least the first
week following randomization.
Daily average energy intake during the trial was 1803
(SD 95.2) kcal (11.8% protein, 15.2% fat, and 73.0% car-
bohydrates, with 29 g/1000 kcal fiber) in the Ma-Pi 2
group, and 1798 (SD 106.3) kcal (18.4% protein, 32.3% fat,
and 49.3% carbohydrates, with 20.5 g/1000 kcal fiber) for
the control group (p = 0.860). For the Ma-Pi 2 diet the
daily average amount of carbohydrate was 335.7 g. As for
the control diet the daily average amount of carbohydrate
was 235.8 g (p < 0.001).
Figure 1 shows the primary and secondary outcomes
results. A significant reduction was observed in both
groups for FBG and for PPBG. The reduction in PPBG
(p = 0.035) levels was significantly greater in patients in
the Ma-Pi 2 group compared with those in the control
group.
Table 1 Effect of Ma-Pi 2 vs. control diet on primary and
secondary outcomes
Dependent variables (% changes) Regression
coefficients
95% CI**
Fasting Blood Glucose (mg/dl) 6.82 1.79; 13.46
Postprandial Blood Glucose (mg/dl) 11.48 5.39; 31.44
HbA1c (%) 3.46 1.28; 5.46
HbA1c (mmol/mol) 3,08 1,21, 5,13
HOMA-IR* 15.14 3.65; 37.51
Total Cholesterol (mg/dl) 18.61 11.52; 22.63
LDL Cholesterol (mg/dl) 26.40 21.37; 34.50
HDL Cholesterol (mg/dl) 4.82 −5.69; 10.22
LDL/HDL Ratio 31.54 20.63; 36.52
Triglycerides (mg/dl) −11.04 −24.41; −2.92
BMI (kg/m2) 2.99 2.42; 3.59
Weight (kg) 3.04 2.39; 3.58
Waist circumference (cm) 2.01 0.08; 3.17
Hip circumference (cm) 1.22 0.4; 1.94
*Wrist circumference was included as covariate for HOMA-IR.
**Coefficients are statistically significant when the 95% CI’s does not
include zero.
Legend: Results of multiple quantile regression analysis evaluating the effect
of Ma-Pi 2 diet on the percentage changes (T0-T21) in biochemical and
anthropometrical measures using a multiple quantile regression model
(adjusted value for age, gender, physical activity and BMI at baseline).
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a significantly greater reduction in HbA1c (p = 0.002)
levels compared with those in the control group. Signifi-
cantly greater median percentage reductions were ob-
served for total cholesterol, LDLc, and the LDL/HDL ratio
in the Ma-Pi 2 group versus the control group (p < 0.001).
No significant change was observed for HDLc levels from
baseline between groups and within groups (p = 0.283).
Median BMI and weight were significantly reduced in
both groups, and those reductions were significantly
higher in the Ma-Pi 2 group compared with the control
group (p < 0.001) (Table 4).
A non-parametric longitudinal data analysis of the
daily FBG and PPBG evidenced a trend curve reduc-
tion in both groups over time (p < 0.001), with a higherTable 2 Number of patients who achieved target blood gluco
Ma-Pi 2 diet
Fasting blood glucose (target value≤ 110 mg/dl) n (%)
Target achievement** 19 (100
Target maintenance** 6 (100
Post-prandial blood glucose (target value ≤ 140 mg/dl)
Target achievement 11 (100
Target maintenance 14 (100
*McNemar test. Coefficients are statistically significant when the 95% CI’s does not
**The percentage of patients that achieved the glycemic target level (both fasting a
of patients that maintained the glycemic target level (both fasting and 2-h after lun
the control group.tendency in the macrobiotic Ma-Pi 2 diet group (p <
0.001). Furthermore, the duration and the type of diet
positively influenced the reduction of both FBG and PPBG
(p < 0.001) (Figure 2).
The results of the multiple quantile regression analysis
(adjusted for age, gender, BMI at baseline, and physical
activity) are reported in Table 1. A significantly higher
percentage reduction of FBG, PPBG, and HbA1c were as-
sociated with the Ma-Pi 2 diet, and a statistically signifi-
cant higher effect on the percentage reductions in the
same group was obtained for total cholesterol, LDL-
cholesterol and LDL/HDL ratio, BMI, weight, and waist
and hip circumference compared with the control group.
The Ma-Pi 2 diet group experienced a significantly greater
reduction of HOMA-IR (adjusted for wrist circumference)
compared with the control group. No statistically signifi-
cant changes in HDL-cholesterol levels were noted in ei-
ther group, whereas the control diet group showed a
significantly higher effect in the reduction of triglyceride
levels compared to the Ma-Pi 2 group even though a re-
duction in triglycerides levels was obtained in both groups,
none of the study participants had triglyceride values in
the higher range after intervention.
Table 2 shows the results obtained by comparing both
groups in the achievement and maintenance of FBG and
PPBG. The percentage of patients who achieved FBG
and PPBG target levels was significantly higher in the Ma-
Pi 2 group compared with the control group. No signifi-
cant difference was found in the percentage of patients
that maintained the glycemic target level (both fasting
and postprandial capillary glucose) between T0 and T21
(Figure 4). For some patients, OAD therapy had to be re-
duced to avoid hypoglycemia. A statistically significant re-
duction in OAD therapy occurred in the Ma-Pi 2 group
compared with the control group (p = 0.018); from a total
of 7 patients on sulfonylurea or glinide and/or DPP-4
inhibitor treatment at baseline, 5 suspended treatment
(resulting in a total daily reduction of 8.5 mg of glinide,
200 mg glicazide, and 10 mg glibencamide). There were
no episodes of hypoglycaemia in both the intervention
group and the control group even though in the Ma-Pi 2se levels after 21 days of dietary treatment
(n. 25) Control diet (n. 26) 95% CI*
n (%) Difference (%) LL UL
) 9 (45) 55.00 33.20 76.80
) 5 (83.33) 16.67 −13.15 46.49
) 8 (53.33) 46.67 21.42 71.91
) 9 (81.82) 18.18 −4.61 40.97
include zero.
nd 2-h after lunch capillary glucose) between T0 and T21 and the percentage
ch capillary glucose) between T0 and T21, in the Ma-Pi 2 group compared with















































































Figure 2 Linear distribution of the daily blood glucose values during the 21 days in and between groups. The figure represents the results of
a non-parametric longitudinal analysis of all daily FBG and PPBG values between baseline and T21 in the Ma-Pi 2 group and the control group.
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In the control group only 1 patient suspended OAD treat-
ment (equating to a total reduction of 60 mg glicazide).
Compliance was good in all patients, with no meals missed
by any patient in either group. There were no reported se-
vere AEs. Pedometer readings revealed no significant dif-
ference in the intensity of physical activity or duration
between the 2 groups.
Discussion
In overweight or obese patients with type 2 diabetes, a
short-term (21 days) nutritional intervention trial using
2 different diets showed that both diets resulted in bene-
ficial effects on metabolic parameters. The macrobiotic
Ma-Pi 2 diet was associated with a greater reduction in
fasting and post prandial plasma glucose, HbA1c, serum
cholesterol, HOMA-IR, BMI, and waist and hip circum-
ferences than the standard control diet.Our study is the first randomized trial to assess and
quantify the reported beneficial effects of the Ma-Pi 2
diet versus the standard nutritional recommendations
for type 2 diabetes [25]. In this trial patients consuming
the Ma-Pi 2 diet experienced a statistically significantly
greater benefit in terms of reduced FBG, PPBG, HbA1c,
and HOMA–IR, compared to patients receiving the con-
trol diet, suggesting that the Ma-Pi 2 macrobiotic diet is
a more effective dietary intervention than the standard
recommended diet for improving metabolic control in
patients with type 2 diabetes. Also, significantly greater
weight loss was obtained in the Ma-Pi 2 diet group com-
pared with the control group, despite consumption of
the same energy content in both diets. The Ma-Pi 2 diet
was also higher in fiber content by up to 10 g/1000 kcal
(50%) than the control diet which may also have contrib-
uted to the greater weight loss in the Ma-Pi 2 diet group;
Langlois et al. conducted a retrospective cohort study of
Table 3 Baseline characteristics according to study group
Median [95% CI] Ma-Pi 2 diet Control diet p value*
(n = 25) (n = 26)
Age (years) 67 [63.8; 70.2] 65 [62.2; 67.8] 0.213
Male, n (%) 11 (44) 14 (53,8) 0.580#
Duration of T2D (years) 7 [3.9; 10.01] 4.5 [1.1; 7.9] 0.494
On Metformin, n (%) 13 (61.9) 20 (90.9) 0.034#
On other OADs, n (%) 7 (33.3) 10 (45.5) 0.537#
Fasting blood glucose (mg/dl) 118 [104.7; 131.3] 127 [115.2; 138.8] 0.888
HbA1c (%) 6.7 [6.2; 7.2] 6.8 [6.6; 7.0] 0.197
HbA1c (mmol/mol) 50 [44; 55] 51 [49; 53] 0.228
HOMA-IR 3.1 [2.1; 4.0] 3.3 [2.1; 4.5] 0.910
Total cholesterol (mg/dl) 176 [156.4; 195.6] 180.5 [160.7; 200.3] 0.865
LDL cholesterol (mg/dl) 102 [86.5; 117.5] 101.5 [89.1; 113.9] 0.749
HDL cholesterol (mg/dl) 46 [41.6; 50.4] 48.5 [44.5; 52.5] 0.428
LDL/HDL ratio 2.4 [2.1; 2.7] 2 [1.7; 2.3] 0.243
Triglycerides (mg/dl) 114 [83.7; 144.3] 119 [97.6; 140.4] 0.644
BMI (kg/m2) 31.3 [29.1; 33.5] 32 [29.5; 34.5] 0.486
Weight (kg) 81.1 [73.7; 88.5] 87 [79.0; 94.9] 0.713
Waist circumference (cm) 107.6 [102.3; 112.9] 105.2 [99.8; 110.6] 0.963
Hip circumference (cm) 108.7 [102; 115.4] 109.7 [104.7; 114.7] 0.821
*Wilcoxon rank sum test.
#Fisher exact test.
Legend: All data showed are a median [95% Confidence Interval CI] unless otherwise noted. Coefficients are statistically significant when the 95% CI’s does not
include zero.
Soare et al. Nutrition & Metabolism 2014, 11:39 Page 8 of 12
http://www.nutritionandmetabolism.com/content/11/1/39the Canadian population and found that dietary fiber in-
take was inversely related with incidence of obesity [32].
A reduction in total cholesterol, LDLc and LDL/HDL
ratio was observed with both diets, but was significantly
higher with the Ma-Pi 2 diet. This could be the result of
a higher intake of wholegrain cereals; this is in line with200 Assessed for e
1
56 Randomize
28 Randomized to Ma-Pi 2 Diet
11 Men, 17 Women
3 Discontinued intervention
1 Reluctance to change diet
2 Personal reasons 

























Figure 3 Consort diagram reflecting flow of study participants througa Cochrane review on the effect of wholegrain cereals on
coronary heart disease that found that short-term dietary
oatmeal intervention was associated with lower total
cholesterol and LDLc [33].
The success of the control diet in improving metabolic
control is supported by previous studies on Mediterraneanligibility
44 Excluded
90 Did not meet inclusion criteria
45 Unable to attend residential schedule 
9 Failure to keep interview appointment
d
28 Randomized to Control Diet
14 Men, 14 Women
2 Discontinued intervention
2 Personal reasons
26 Included in any analysis for 
present report
h the study.
Table 4 Primary and secondary outcomes comparison between groups at baseline and after 21 days on the prescribed diets
Median [1st-3rd quartiles] Ma-Pi 2 diet (n = 25) Control diet (n = 26)
Baseline T21 Absolute change Percent change Baseline T21 Absolute change Percent change p value*
Fasting blood
glucose (mg/dl)
129 (111; 149) 95 (91; 100) 34 (21; 44) 26.2 (18.7; 34.1) 126 (112; 150) 110 (99; 115) 22.8 (8.1; 44.6) 16.9 (6.9; 30.1) 0.073
Post prandial blood
glucose (mg/dl)
134 (112; 179) 100 (94; 106) 34 (18; 75.5) 23.1 (15.9; 42.9) 144 (128; 210) 127 (108; 151) 15.3 (−1.6; 58.6) 8.7 (−1.9; 50.3) 0.035
HbA1c (%) 6.7 (6.2; 7.7) 6.3 (5.9; 7) 0.4 (0.2; 0.6) 6.2 (3.3; 8.3) 6.8 (6.4; 7.1) 6.6 (6.2; 7) 0.2 (0.1; 0.4) 2.2 (1.5; 5) 0.002
HOMA-IR 3.1 (1.2; 4.1) 0.98 (0.61; 1.98) 1.3 (0.1; 2.9) 51.4 (11.7; 78.3) 3.3 (0.9; 4.6) 1.6 (1.2; 2.4) 1.4 (−0.2; 2.3) 40.4 (−21.9; 62) 0.142
Total cholesterol (mg/dl) 176 (155; 217) 120 (102; 138) 57 (40; 65) 32 (23.8; 38.6) 180.5 (150.2; 210.8) 154 (133; 185) 24 (16; 43) 12.3 (9.9; 23) < 0.001
LDL cholesterol (mg/dl) 102 (84; 133) 62 (39; 69) 45 (33; 58) 47.9 (33.5; 53.6) 101.5 (84.8; 123.5) 81 (66; 105) 20 (12.3; 31.3) 19.7 (13.5; 27.8) < 0.001
HDL cholesterol (mg/dl) 46 (38; 52) 42 (36; 51) 4 (−1; 8) 7.5 (−2.2; 17.1) 48.5 (43; 55.8) 47 (40; 56) 0.5 (−2; 6.8) 0.9 (−4.4; 11.5) 0.283
LDL/HDL ratio 2.4 (2; 3) 1.3 (0.9; 2.4) 0.9 (0.5; 1.3) 38.5 (29.3; 49.9) 2 (1.8; 2.6) 1.8 (1.3; 2.4) 0.4 (0.1; 0.7) 17.2 (5.9; 29.5) < 0.001
BMI (kg/m2) 31.3 (29.9; 36.8) 29.5 (28.2; 34.6) 2 (1.8; 2.4) 5.9 (5.4; 6.9) 32 (28.2; 35.9) 30.8 (27.3; 34.6) 1 (0.7; 1.3) 2.9 (2.4; 4.1) < 0.001
Weight (kg) 81.1 (75.6; 99.1) 77 (70; 94) 5.5 (4.4; 6) 6.3 (5.6; 7.2) 87 (79; 103.9) 83 (75; 100) 2.8 (2; 3.6) 2.9 (2.4; 4.2) < 0.001
Waist circumference (cm) 107.6 (97.9; 114.7) 103 (96; 112) 4.2 (1.4; 6.5) 3.9 (1.6; 5.3) 105.2 (101.6; 117.5) 103 (101; 113) 2.3 (0.9; 4) 1.9 (0.9; 2.9) 0.046
Hip circumference (cm) 108.7 (102.5; 23.8) 105 (99; 120) 3.4 (2; 5.2) 3.1 (1.8; 4) 109.7 (102.6; 118.4) 108 (101; 118.4) 1.8 (1; 2.5) 1.6 (0.8; 2.4) 0.006




















Figure 4 Percentage of patients who achieved or maintained target blood glucose levels after 21 days of dietary treatment.
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http://www.nutritionandmetabolism.com/content/11/1/39diets. A systematic review and meta-analysis found signifi-
cant improvement in glycemic control in low-carbohydrate,
Mediterranean, and high-protein diets and a greater weight
loss in low-carbohydrate and Mediterranean diets com-
pared with their respective control diets [34]; A short trial
on the effect of a high-protein/low-carbohydrate diet on
glucose control showed a reduction in circulating glucose
concentration in patients with untreated type 2 diabetes
[35]; A Mediterranean diet, rich in monounsaturated fatty
acids and in complex carbohydrate but not high in protein
was associated with lower HbA1c levels and 2 hour post-
meal glucose levels independently of variations in age, adi-
posity, energy intake, and physical activity in 901 patients
with type 2 diabetes [36].
Overall the positive results obtained with the two diets
in our short-term study may be explained in part by the
wellbeing (emotional and physical) state of our patients
since they were located close to the sea, had a strict con-
trol on the caloric intake, perform regular (monitored)
physical activity improving their overall quality of life.
The greater effect of the Ma-Pi 2 diet compared to the
control diet on a number of metabolic parameters may
be due to several factors, from changes in inflammation
and/or oxidative stress [37] to the composition of micro-
biota [22]. Ongoing studies should elucidate all these is-
sues, hence a long-term sustainability of the Ma-Pi 2 diet,
in particular the acceptance and adherence of the patient
to the diet, the implying costs in the patient management
remain to be proven.
Patient compliance and adherence to recommended
therapeutic diets for diabetes are essential for the diets to
be able to produce clinically-significant improvements in
patient outcomes, and positive results achieved with diets
in clinical trials are often difficult to replicate in real-life
practice [38]. In the study presented here, participants
attended 2-hour meetings daily for nutritional educa-
tion and cooking instructions in their respective hotelsconducted by a physician and a registered dietitian and/or
a cooking instructor. This was done to encourage continu-
ation of the respective diets once the trial was completed.
Our study had a number of limitations including short
duration, lack of blinding, and relatively small sample
size. The short duration was due to the difficulty in ac-
commodating participants for 24 hours per day and re-
quiring them not to leave their respective hotels for the
duration of the trial. A longer-term trial of this type is
unlikely to be successful due to the lower number of vol-
unteers and higher number of dropouts that would be
likely with increased duration. Participant blinding was
impossible due to the distinct differences in the ingredi-
ents and therefore taste and appearance of the 2 diets
used. Similarly, it was also not possible to blind the med-
ical staff present at the hotels. However, the investigators
involved in follow-up and blood testing were blinded to
the treatment groups.
Conclusions
All patients in the Ma-Pi 2 diet group had their glucose
levels reduced to the point of being comparable to sub-
jects without type 2 diabetes (target values), following
21-day intervention in a supervised environment. Fur-
ther long-term follow-up studies are needed to confirm
these results and the use of this diet in real-life practice
must also be investigated to demonstrate patient accept-
ance and compliance.
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